Key facts
- NeuroXess’s last known valuation is $48.4M (Dec 2021).
- It has raised $15.2M; the latest was Early Stage VC in Feb 2026.
- Notable investors include HSG (Hong Kong), Yonghua Capital, New Alliance Capital, Chengdu Bio-Town Investment, Sailing Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for NeuroXess
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroXess are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroXess
Manufacturer of a brain-computer interface technology intended to advance neurological research and medical applications. The company offers flexible implantable electrodes, silk-protein biomaterials, advanced decoding algorithms, and wireless systems, enabling healthcare institutions and research organizations to achieve precise neural interaction and improved patient rehabilitation.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 70
- Website
- neuroxess.com/
- Ownership
- Privately Held (backing)
NeuroXess doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroXess shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroXess in its N-PORT filings yet. We sweep new filings monthly.